News & Updates

Canakinumab hits mark in COVID-19-related pneumonia

12 Jan 2021 by

The interleukin (IL)-1β antibody canakinumab has demonstrated a promising efficacy signal in patients with COVID-19-related pneumonia, reducing the need for invasive mechanical ventilation and improving clinical status, according to a study.

Canakinumab hits mark in COVID-19-related pneumonia

12 Jan 2021

ACEI/ARBs superior to CCBs at albuminuria reduction in nephropathy due to diabetes, hypertension

12 Jan 2021 by

Renin-angiotensin system inhibitors perform better than calcium channel blockers (CCB) at decreasing albuminuria among diabetic and hypertensive patients with nephropathy, according to the results of a systematic review and meta-analysis.

ACEI/ARBs superior to CCBs at albuminuria reduction in nephropathy due to diabetes, hypertension

12 Jan 2021

Beti-cel gene therapy shows durable safety, efficacy for transfusion-dependent β-thalassaemia

12 Jan 2021 by

Long-term betibeglogene autotemcel (beti-cel) gene therapy led to durable, stable responses in patients with transfusion-dependent β-thalassaemia (TDT), according to two studies presented at ASH 2020.

Beti-cel gene therapy shows durable safety, efficacy for transfusion-dependent β-thalassaemia

12 Jan 2021

Injectable risperidone effective against acutely exacerbated schizophrenia

12 Jan 2021

Use of long-acting injectable risperidone appears to produce rapid and progressive reduction in symptoms of schizophrenia patients with acute exacerbation, eliminating the need for oral risperidone supplementation or loading doses, according to a study.

Injectable risperidone effective against acutely exacerbated schizophrenia

12 Jan 2021

Combined PARP, ATR Inhibitors potent against prostate cancer with ATM loss

11 Jan 2021 by

A fraction of patients with aggressive prostate cancer have ATM-deficient disease, and this subgroup appears to be most sensitive to the combination of oral drugs targeting PARP* and ATR**, according to a study.

Combined PARP, ATR Inhibitors potent against prostate cancer with ATM loss

11 Jan 2021

High-dose vit D does not prevent falls in elderly

09 Jan 2021 by

Not only is high-dose vitamin D supplementation of no help in preventing falls in older adults, it may raise safety concerns at doses ≥1,000 IU/day, according to the STURDY* trial.

High-dose vit D does not prevent falls in elderly

09 Jan 2021

Bezlotoxumab prevents recurrent Clostridioides difficile infection

09 Jan 2021

Bezlotoxumab is both safe and effective for the prevention of recurrent Clostridioides difficile infection (rCDI), results of a meta-analysis have shown. Moreover, bezlotoxumab may be a good therapeutic option for severe rather than mild CDI.

Bezlotoxumab prevents recurrent Clostridioides difficile infection

09 Jan 2021

Paracetamol, parecoxib show promise in acute renal colic

09 Jan 2021

In the treatment of patients with acute renal colic, paracetamol and parecoxib are equally effective at dulling pain, reducing the need for rescue analgesia with minimal adverse events, as shown in a study.

Paracetamol, parecoxib show promise in acute renal colic

09 Jan 2021

ALL treatment: Current settings, future goals

08 Jan 2021 by

Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.

ALL treatment: Current settings, future goals

08 Jan 2021

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?

08 Jan 2021 by

Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?

08 Jan 2021

News & Updates

Filter by Specialty:

Specialty:

Canakinumab hits mark in COVID-19-related pneumonia

Canakinumab hits mark in COVID-19-related pneumonia

ACEI/ARBs superior to CCBs at albuminuria reduction in nephropathy due to diabetes, hypertension

ACEI/ARBs superior to CCBs at albuminuria reduction in nephropathy due to diabetes, hypertension

Beti-cel gene therapy shows durable safety, efficacy for transfusion-dependent β-thalassaemia

Beti-cel gene therapy shows durable safety, efficacy for transfusion-dependent β-thalassaemia

Injectable risperidone effective against acutely exacerbated schizophrenia

Injectable risperidone effective against acutely exacerbated schizophrenia

Combined PARP, ATR Inhibitors potent against prostate cancer with ATM loss

Combined PARP, ATR Inhibitors potent against prostate cancer with ATM loss

High-dose vit D does not prevent falls in elderly

High-dose vit D does not prevent falls in elderly

Bezlotoxumab prevents recurrent Clostridioides difficile infection

Bezlotoxumab prevents recurrent Clostridioides difficile infection

Paracetamol, parecoxib show promise in acute renal colic

Paracetamol, parecoxib show promise in acute renal colic

ALL treatment: Current settings, future goals

ALL treatment: Current settings, future goals

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?